Holen Sie sich die Stockscreener-App
8.475
1.91%
-0.165
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AUPH?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$8.64
Offen:
$8.67
24-Stunden-Volumen:
1.57M
Relative Volume:
1.32
Marktkapitalisierung:
$1.10B
Einnahmen:
$175.51M
Nettoeinkommen (Verlust:
$-78.02M
KGV:
-15.99
EPS:
-0.53
Netto-Cashflow:
$-34.18M
1W Leistung:
+8.24%
1M Leistung:
+8.10%
6M Leistung:
-7.58%
1J Leistung:
+48.42%
1-Tages-Spanne:
$8.44
$8.86
1-Wochen-Bereich:
$7.82
$8.86
52-Wochen-Spanne:
$5.195
$10.67
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Firmenname
Aurinia Pharmaceuticals Inc
Sektor
Branche
Telefon
250-744-2487
Adresse
#140, 14315 - 118 AVENUE, EDMONTON, BC
Vergleichen Sie AUPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
8.475 | 1.10B | 175.51M | -78.02M | -34.18M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.10 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.23 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
550.76 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.59 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-04 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-05-05 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-05-05 | Eingeleitet | Cowen | Outperform |
| 2020-01-10 | Eingeleitet | Jefferies | Buy |
| 2019-12-16 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-16 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-02-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-10-30 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-03-22 | Bestätigt | FBR & Co. | Outperform |
| 2016-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-17 | Bestätigt | H.C. Wainwright | Buy |
| 2016-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-05-08 | Eingeleitet | MLV & Co | Buy |
Alle ansehen
Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten
With 51% institutional ownership, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a favorite amongst the big guns - Yahoo Finance
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA
California State Teachers Retirement System Sells 13,824 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Bank of America Corp DE - Defense World
Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock? - MSN
As Edmonton biotech industry booms, Launa Aspeslet steps up to guide further success - Taproot Edmonton
Wellington Management Group LLP Buys New Shares in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress - mx.advfn.com
Millennium Management LLC Increases Stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SDIG, AUPH and LICY - ACCESS Newswire
(AUPH) Trading Signals - news.stocktradersdaily.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.27 Million Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - InsuranceNewsNet
Ameriprise Financial Inc. Acquires 26,981 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of AUPH, IRNT and RSKD - ACCESS Newswire
Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock? - MSN
BNP Paribas Financial Markets Sells 14,003 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Is The Options Market Predicting A Spike In Aurinia Pharmaceuticals (AUPH) Stock? - Barchart.com
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Nuveen Asset Management LLC Increases Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Cetera Investment Advisers Purchases 2,000 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
(AUPH) Technical Data - news.stocktradersdaily.com
Deutsche Bank AG Purchases 50,575 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
US Stocks Likely To Open On A Mixed Note: 'Nothing Good Happens Above A 5% Yield,' Says Expert - Benzinga
Aurinia Pharmaceuticals (AUPH) Reports Positive Lupkinis Trial R - GuruFocus
Aurinia Pharmaceuticals (AUPH) Reports Positive Lupkinis Trial Results | AUPH Stock News - GuruFocus
Aurinia Pharmaceuticals’ LUPKYNIS Shows Promising Results in Lupus Nephritis Study - TipRanks
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Strong Earnings Are Of Good Quality - simplywall.st
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
Aurinia Pharmaceuticals Inc. Just Recorded A 60% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Leerink Partnrs Has Positive Outlook of AUPH Q2 Earnings - Defense World
Aurinia Pharmaceuticals Approves New Equity Incentive Plan - TipRanks
Aurinia Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st
Aurinia Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Transcript : Aurinia Pharmaceuticals Inc.Shareholder/Analyst Call - marketscreener.com
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2025 Earnings Call Transcript - MSN
Aurinia Pharmaceuticals Financial Update and Strategic Growth Plans - Zenopa
Aurinia Pharmaceuticals (AUPH) Reports Strong Q1 Earnings Beat - GuruFocus
Price T Rowe Associates Inc. MD Has $468,000 Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Aurinia outlines $250M–$260M 2025 revenue target as LUPKYNIS sales climb 25% and operational efficiency improves - MSN
Decoding Aurinia Pharmaceuticals Inc (AUPH): A Strategic SWOT In - GuruFocus
Company News for May 13, 2025 - Yahoo Finance
Aurinia Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
Document - SEC.gov
Aurinia Pharmaceuticals Q1 2025 Earnings: Strong Growth Amid Challenges - TipRanks
Aurinia: Q1 Earnings Snapshot - MySA
Aurinia Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance - Benzinga
Leerink maintains Aurinia stock Outperform with $10 target - Investing.com
Aurinia Stock Rallies On Upbeat Q1 Earnings, CEO Expects Strong Performance in 2025: Retail Sentiment Brightens - Investing.com India
AUPH Reports Q1 Revenue Exceeding Expectations with Strong Outlo - GuruFocus
Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Finanzdaten der Aurinia Pharmaceuticals Inc-Aktie (AUPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aurinia Pharmaceuticals Inc-Aktie (AUPH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Greenleaf Peter | Chief Executive Officer |
Mar 03 '25 |
Sale |
8.00 |
195,593 |
1,564,744 |
1,953,892 |
| Greenleaf Peter | Chief Executive Officer |
Mar 04 '25 |
Sale |
7.92 |
164,947 |
1,306,380 |
1,788,945 |
| Keenan Greg | Chief Medical Officer |
Mar 03 '25 |
Sale |
8.00 |
12,239 |
97,912 |
161,789 |
| Miller Joseph M | Chief Financial Officer |
Mar 03 '25 |
Sale |
8.00 |
61,859 |
494,872 |
633,515 |
| Miller Joseph M | Chief Financial Officer |
Mar 04 '25 |
Sale |
7.92 |
56,154 |
444,740 |
577,361 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 03 '25 |
Sale |
8.00 |
64,872 |
518,976 |
566,883 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 04 '25 |
Sale |
7.92 |
57,607 |
456,247 |
509,276 |
| Donley Matthew Maxwell | Chief Operating Officer |
Mar 03 '25 |
Sale |
8.00 |
65,902 |
527,216 |
739,456 |
| Donley Matthew Maxwell | Chief Operating Officer |
Mar 04 '25 |
Sale |
7.92 |
58,991 |
467,209 |
680,465 |
| TANG KEVIN | Director |
Mar 04 '25 |
Buy |
7.96 |
748,038 |
5,953,304 |
10,029,500 |
0.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):